CureDuchenne is sharing a community letter from Sarepta announcing a strategic company restructuring and pipeline prioritization plan. Additionally, Sarepta shared that the U.S. FDA has requested and Sarepta has agreed to include a […]
Capricor Therapeutics, which received early funding from CureDuchenne, announced regulatory updates for their Deramiocel program to treat Duchenne. The FDA informed Capricor of its intent to hold an Advisory Committee […]
Satellos Biosciences announced their Phase 1b results from their open-label study with SAT-3247, which aims to improve muscle regeneration in Duchenne. SAT-3247 was safe and well-tolerated in 5 individuals with […]
Newport Beach, Calif. and Edmonton, Canada (May 22, 2025) – CureDuchenne Ventures announced an initial $1M investment in Entos Pharmaceuticals Inc (Entos), a biotech company that develops genetic medicines utilizing […]
CureDuchenne provided early funding to Entrada Therapeutics. Entrada has received regulatory authorization in Europe to initiate a Phase 1/2 clinical trial of ENTR-601-44 in ambulatory individuals with Duchenne amenable to […]
Premier Wine Tasting and Auction Brought Acclaimed Napa Valley Vintners Together with Miami Philanthropists to Benefit Global Nonprofit CureDuchenne MIAMI, FL, April 16, 2025 – CureDuchenne, a global nonprofit committed to […]
Download PDF HERE CHAMPIONS SPONSORSHIP OPPORTUNITIES 2025
Wave Life Science Exon Skipping in Duchenne Wave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study: An update on Wave’s Phase 2 FORWARD-53 trial of WE-N531, Wave’s […]
Napa in Miami 2025 Auction Catalog Bid by proxy by emailing okairy@dev.cureduchenne.com
